GlassScriptPhysician profile
Rishi Sawhney
NPI 1750346698
$10,887.45
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,778 · 2020: $1,000 · 2021: $1,712 · 2022: $1,075 · 2023: $17.48 · 2024: $4,305.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,267 · Food and Beverage: $55.17.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,267.00 |
| Food and Beverage | $55.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $8,195.36 | 2019-2024 | Tavalisse, Rezlidhia |
| Astrazeneca Pharmaceuticals LP | $1,050.00 | 2024 | Calquence, Lynparza |
| Daiichi Sankyo INC. | $550.00 | 2022 | |
| Beigene USA, INC. | $525.00 | 2022 | |
| Emd Serono, INC. | $500.00 | 2021 | |
| Pfizer INC. | $37.69 | 2024 | |
| Incyte Corporation | $17.48 | 2023 | Jakafi |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rishi Sawhney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.